| hydrocortisone / Generic mfg. |
NCT00006371: A Phase II Trial of Early Medical Adrenalectomy for "D0.5" Prostate Cancer |
|
|
| Terminated | 2 | 2 | US | aminoglutethimide, Cytadren, ketoconazole, Nizoral, therapeutic hydrocortisone, corticosteroid | H. Lee Moffitt Cancer Center and Research Institute, National Cancer Institute (NCI), Janssen Pharmaceuticals | Prostate Cancer | 12/01 | 12/01 | | |
NCT00181597: Trilostane for Androgen-Independent Prostate Cancer |
|
|
| Completed | 2 | 24 | US | Trilostane, Hydrocortisone | Genzyme, a Sanofi Company | Prostate Cancer, Prostate Adenocarcinoma | 01/06 | 01/06 | | |
NCT00447473: Trial of GM-CSF Given in Combination With Ketoconazole and Mitoxantrone in Patients With Progressive Prostate Cancer |
|
|
| Terminated | 2 | 31 | US | GM-CSF, Leukine, Ketoconazole, Nizoral, Extina, Xolegel, Kuric, Mitoxantrone, Novantrone, Mitoxantrone | The Methodist Hospital Research Institute, Bayer | Prostatic Neoplasms | 08/08 | 09/08 | | |
NCT00298155: Maximal Suppression of the Androgen Axis in Clinically Localized Prostate Cancer |
|
|
| Completed | 2 | 35 | US | goserelin with dutasteride, goserelin with bicalutamide and dutasteride, goserelin with bicalutamide and dutasteride and ketoconazole | University of Washington, GlaxoSmithKline, AstraZeneca | Cancer, Prostate Neoplasms | 06/10 | 01/14 | | |
KHAD, NCT00673127: Ketoconazole, Hydrocortisone and Dutasteride in Asymptomatic Hormone Refractory Prostate Cancer |
|
|
| Completed | 2 | 57 | US, Canada | Ketoconazole, Hydrocortisone and Dutasteride, Dutasteride=Avodart | Beth Israel Deaconess Medical Center, Massachusetts General Hospital, Dana-Farber Cancer Institute, Sunnybrook Health Sciences Centre, Oregon Health and Science University, M.D. Anderson Cancer Center, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Prostate Cancer | 02/12 | 12/12 | | |
NCT01267266: Saracatinib in Treating Patients With Prostate Cancer |
|
|
| Terminated | 2 | 31 | US | saracatinib, AZD0530, hydrocortisone/placebo | National Cancer Institute (NCI) | Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer | 09/12 | 11/13 | | |
NCT00895310: Use of Low Dose Ketoconazole in Prostate Cancer That Does Not Respond to Hormone Therapy and Prior Chemotherapy |
|
|
| Completed | 2 | 30 | US | Ketoconazole, Nizoral, Hydrocortisone, Cortef | University of California, Davis | Prostate Cancer | 12/14 | 05/15 | | |
NCT00953576: Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer |
|
|
| Terminated | 1/2 | 11 | US | ketoconazole, Nizoral, hydrocortisone, Cortef, Hydrocortone, dutasteride, Avodart, lapatinib, lapatinib ditosylate, Tyverb | Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Brigham and Women's Hospital, Massachusetts General Hospital, Prostate Cancer Foundation Clinical Research Consortium, GlaxoSmithKline | Prostate Cancer | 04/13 | 04/13 | | |
